The FDA flagged a potential safety signal after four patient deaths in a trial testing a schizophrenia drug, Argenx faces an unusual setback, and more pharma news.
The FDA flagged a potential safety signal after four patient deaths in a trial testing a schizophrenia drug, Argenx faces an unusual setback, and more pharma news.
<iframe src="https://statesidedaily.com/embed/cluster/d99eaa67023f2f140dc728612a1a5c7d0ae8f1ed" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more"></iframe>
